Arrowhead Research | ARWR - Pre Tax Profit


Arrowhead Research reported $-178.9M in Pre-Tax Profit for its fiscal quarter ending in June of 2026.





Pre Tax Profit Change Date
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
Alnylam Pharmaceuticals USD 177.81M 43.85M Jun/2026
Anika Therapeutics USD 764K 3M Dec/2025
Arrowhead Research USD -178.9M 41.34M Jun/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Incyte USD 751.51M 407.91M Jun/2026
Ionis Pharmaceuticals USD -114M 21M Jun/2026
Ligand Pharmaceuticals USD -24.26M 81.04M Mar/2026
Merck USD -3.53B 6.95B Mar/2026
Moderna USD -1.33B 535M Mar/2026
Nektar Therapeutics USD -43.09M 8.39M Mar/2026
Novartis USD 4.27B 430M Jun/2026
Sarepta Therapeutics USD -1.75M 344.92M Jun/2026
TG Therapeutics USD 10.23M 10.13M Jun/2026
Ultragenyx Pharmaceutical USD -91M 93M Jun/2026
Vertex Pharmaceuticals USD 1.39B 138.9M Jun/2026
Xencor USD -21.92M 106.72M Jun/2026